Sanofi is a leading global biopharmaceutical company. The company is represented on five continents; its headcount is about 110,000 people globally. Sanofi acts to protect health, enhance life and respond to the hopes and potential healthcare needs of 7 billion people around the world.
From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, making a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
Sanofi has been present in Russia since 1970 and offers patients a broad portfolio of original drugs, generics and OTC drugs in key therapeutic areas (diabetes, oncology, cardiovascular disorders, nervous system disorders, internal diseases, thrombosis, rare diseases and multiple sclerosis), as well as vaccines. About 2 000 employees work at Sanofi Russia. Sanofi is the leader of the Russian pharmaceutical market.
Sanofi is among the first international companies to localize its drug production in Russia. “Sanofi-Aventis Vostok” site in Orel constructed in 2010 according to the international guidelines and Good Manufacturing Practice (GMP) standards, in 2013 switched to full cycle production of modern insulin. In 2012, the site launched the production of drugs against cancer.
“Sanofi-Aventis Vostok” is the first full cycle production site for novel insulin in Russia, its manufacturing capacities are sufficient to satisfy the needs of diabetic patients in modern insulin both in Russia and in European Union countries. In 2016, the plant successfully passed European inspection and obtained a GMP certificate of the European Medicines Agency (EMA) to secure export of insulin manufactured in the Orel region to the European countries. In May 2016, “zero kilometer” of the production of the last generation basal insulin was launched at “Sanofi-Aventis Vostok” plant. In June 2017, Sanofi announced the export launch of insulins produced at Sanofi-Aventis Vostok plant to the European Union countries.
In October 2017, Sanofi signed special investment contract (SPIC) with Ministry of Industry and Trade, and Orel region administration for the modernization of pharmaceutical production at the Sanofi-Aventis Vostok plant in the Orel region. SPIC agreement aims as well at the development of pharmaceutical products manufacturing that has no analogues produced in the Russian Federation.
Access to healthcare is one of significant issues, which humanity is facing today. As a leading global healthcare company, Sanofi is committed to use its knowledge and expertise to improve patient access to quality healthcare for a broad range of people globally.
 IMS data for 2017. Source: Sanofi.
 Excluding production of pharmaceutical substance